Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer

Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer

Chimeric antigen receptor (CAR) T cell is a promising method in cancer immunotherapy but faces many challenges in solid tumors. One of the major problems was immunosuppression caused by PD-1. In our study, the expression of c-Met in GC was analyzed from TCGA datasets, GC tissues, and cell lines. The...

Full description

Bibliographic Details
Main Authors: Cong Chen, Yan-Mei Gu, Fan Zhang, Zheng-Chao Zhang, Ya-Ting Zhang, Yi-Di He, Ling Wang, Ning Zhou, Fu-Tian Tang, Hong-Jian Liu, Yu-Min Li
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
gastric cancer
car-t
c-met
pd1/cd28
immunotherapy
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1901434

Similar Items

Similar Items